Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Docket		Date Filed	2018-04-09
Court	District Court, D. New Jersey	Date Terminated	2022-07-27
Cause	15:1126 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Jessica S. Allen
Parties	ADAPT PHARMA OPERATIONS LIMITED
Patents	7,977,376; 9,211,253; 9,468,747; 9,480,644; 9,561,177; 9,707,226
Attorneys	HECTOR DANIEL RUIZ
Firms	Saul Ewing Arnstein & Lehr LLP
Link to Docket	External link to docket

Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-09				External link to document
2018-04-09	1		7,977,376 B2 7/2011 Singh et al .............…United States Patent Nos. 9,480,644 (the “’644 patent”) and 9,707,226 (the “’226 patent”) (collectively… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C… The Patent-in-suit 12. On November 1, 2016, the United States Patent and Trademark… the ’644 patent, entitled, “Nasal Drug Products and Methods of Their Use.” The ’644 patent is assigned	External link to document

Adapt Pharma v. Teva Pharmaceuticals: Litigation Summary, Patent Analysis, and Generic Narcan Entry Risk

Last updated: August 9, 2026

Adapt Pharma Operations Limited sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey after Teva filed an abbreviated new drug application seeking approval for a generic naloxone hydrochloride nasal spray. The dispute concerned patents protecting Narcan 4 mg nasal spray, including formulation and nasal-delivery claims. The case was resolved through a settlement and dismissal rather than a reported trial judgment on validity or infringement. Teva later obtained FDA approval for a generic naloxone nasal spray and entered the U.S. market.

What was Adapt Pharma v. Teva Pharmaceuticals about?

The case involved Teva's proposed generic version of Narcan, a naloxone hydrochloride nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose.

Adapt Pharma marketed Narcan in the United States. Emergent BioSolutions later acquired Adapt Pharma, including the Narcan business. Teva's ANDA filing triggered a Hatch-Waxman patent dispute because Teva certified that the listed Adapt patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

Case item	Detail
Case name	Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:18-cv-05752
Filing year	2018
Branded product	Narcan naloxone hydrochloride nasal spray
Proposed generic	Teva naloxone hydrochloride nasal spray
Legal pathway	Hatch-Waxman ANDA litigation
Principal dispute	Patent infringement and Paragraph IV certification
Outcome	Settlement and dismissal; no reported merits judgment
Regulatory result	FDA approval and later commercial availability of Teva generic naloxone nasal spray

FDA-approved naloxone nasal spray is a small-molecule drug-device combination product. The litigation therefore involved both the drug formulation and the nasal-delivery configuration rather than a biologic or biosimilar pathway. [1]

What patents protected Narcan in the Teva litigation?

The litigation centered on patents listed for Narcan and directed to intranasal naloxone administration and nasal-delivery technology. Public patent records identify the following Adapt-related patents as part of the Narcan patent estate:

Patent	Subject matter	Listed or asserted relevance	Nominal term reference
U.S. Patent No. 9,604,008	Intranasal administration of naloxone	Naloxone nasal formulation and administration parameters	Generally tied to a 2033 expiration period, subject to patent-term adjustments
U.S. Patent No. 9,629,965	Nasal delivery device	Device and delivery architecture used for intranasal administration	Generally tied to a 2033 expiration period, subject to patent-term adjustments
Related continuation patents	Formulation, device, and administration claims	Broader Narcan protection and follow-on enforcement	Expiration varies by patent and statutory term

The patents were important because Narcan's commercial value depends on a formulation that delivers an effective naloxone dose through the nasal route without requiring assembly, injection, or specialized medical training. Claims directed to pH, concentration, dose volume, spray characteristics, container configuration, and actuation can create separate infringement positions even when the active ingredient is off-patent.

Patent expiration dates must be confirmed against the current FDA Orange Book, USPTO patent records, terminal disclaimers, and patent-term-adjustment calculations. A nominal 20-year term from the earliest effective nonprovisional filing date is not always the operative expiration date.

What formulations were protected?

The relevant technology generally covered an aqueous naloxone formulation administered through a nasal spray device. The formulation claims were directed to factors such as:

• Naloxone hydrochloride concentration;
• Solution pH;
• Dose volume delivered per actuation;
• Intranasal administration without needle-based injection;
• Device performance and spray delivery;
• Use in reversing opioid-induced respiratory depression.

A generic applicant can design around some formulation claims by changing concentration, excipients, pH, device geometry, or dose volume. That design-around strategy may be limited when the FDA-approved product's therapeutic and usability requirements narrow the practical formulation range.

How strong was the Narcan patent estate?

The estate was commercially meaningful but not uniformly strong across every potential claim. Device patents can be vulnerable to noninfringement arguments if a generic uses a different actuator, nozzle, reservoir, or spray mechanism. Formulation patents can face validity challenges based on prior intranasal naloxone work, obviousness, written-description support, enablement, and claim construction.

The estate's practical strength came from claim stacking. A generic product could avoid one patent and still face exposure under another patent covering formulation, administration, or device structure. The litigation also imposed a regulatory delay because a Paragraph IV suit ordinarily triggers a statutory 30-month stay of ANDA approval, subject to exceptions and court action. [2]

What was Teva's Paragraph IV challenge?

Teva's ANDA included a Paragraph IV certification for one or more Orange Book-listed Narcan patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Adapt's infringement complaint was the statutory response to that certification. Filing the action created the possibility of a 30-month stay of FDA approval under the Hatch-Waxman Act. The stay mechanism gives the brand company time to litigate before commercial generic entry, although settlement can establish an earlier agreed launch date.

The public case record does not establish a final judicial ruling that Teva infringed a valid and enforceable Narcan patent. It also does not establish that the asserted patents were invalid. The case ended without a published claim-construction ruling, trial verdict, or appellate merits opinion resolving those issues.

When did Teva's generic naloxone product enter the market?

Teva subsequently received FDA approval for naloxone hydrochloride nasal spray, 4 mg/0.1 mL. The product was approved as a generic version of Narcan nasal spray and was marketed as a lower-cost alternative to the branded product. [3]

Milestone	Business significance
ANDA filing	Initiated the patent dispute and regulatory review
Adapt complaint in 2018	Triggered Hatch-Waxman litigation
Settlement and dismissal	Ended the federal case without a reported merits judgment
FDA approval of Teva nasal spray	Removed the regulatory barrier to generic commercialization
Commercial launch	Created direct price and access competition for Narcan

Teva announced the product as the first generic naloxone hydrochloride nasal spray in the United States. The launch increased competitive pressure on Emergent's Narcan franchise and expanded access to an opioid-overdose reversal product. [4]

What is the Orange Book status of Narcan?

Narcan is listed in the FDA Orange Book as an approved naloxone hydrochloride nasal spray product. Orange Book listings identify patents that the NDA holder asserts cover the approved drug, including patents relevant to formulation, method of use, or delivery system technology.

Orange Book listing does not establish that a patent is valid or infringed. It provides notice to ANDA applicants and determines whether a Paragraph IV certification may trigger litigation and a statutory approval stay.

For Narcan, the commercial patent analysis should distinguish among:

1. Patents listed for the approved product;
2. Patents asserted in the Teva complaint;
3. Continuation or later-issued patents;
4. Unlisted patents that may support separate litigation;
5. Regulatory exclusivity independent of patent protection.

FDA approval of a generic does not itself cancel the brand's patents. It indicates that the FDA's approval process and any applicable litigation-related regulatory barrier no longer prevented approval.

What was the litigation outcome?

The case was resolved by settlement and dismissal. The publicly available litigation record does not disclose the complete economic or launch terms. The settlement appears to have permitted Teva to proceed toward generic approval and commercialization under terms negotiated between the parties.

Issue	Resolution
Infringement	No reported final merits determination
Validity	No reported final merits determination
Enforceability	No reported final merits determination
ANDA approval	Teva later obtained FDA approval
Generic launch	Teva entered the naloxone nasal-spray market
Settlement terms	Not fully public in the court record
Precedential value	Limited; no reported claim-construction or appellate ruling

Settlement should not be treated as proof that Adapt's patents were weak or that Teva's product was noninfringing. Brand and generic companies often settle to allocate launch risk, litigation cost, regulatory timing, and commercial uncertainty.

Did the case involve a reverse-payment settlement?

The public case materials do not provide sufficient evidence to characterize the agreement as an unlawful reverse-payment settlement. A full antitrust assessment would require the settlement agreement, payment terms, ancillary commercial arrangements, launch date, licenses, and any restrictions on Teva's conduct.

A conventional patent settlement may include:

• A license to the generic applicant;
• An agreed launch date;
• A covenant not to sue;
• Restrictions tied to patent expiry;
• Authorized-generic provisions;
• Supply or distribution terms;
• No payment from the brand to the generic, or a payment supported by a separate service or transaction.

Under FTC v. Actavis, a large and unexplained payment from a brand company to a generic company can raise antitrust concerns, but the Supreme Court requires a rule-of-reason analysis rather than automatic condemnation. [5] The public docket alone does not establish that the Adapt-Teva settlement contained a disqualifying payment.

What litigation affected Narcan generic entry?

The Teva matter was one of the principal patent disputes involving generic Narcan nasal spray. Other ANDA applicants could face similar claims if they pursued substantially equivalent formulations or delivery devices.

The relevant litigation risks included:

• Infringement of formulation claims;
• Infringement of device claims;
• Induced infringement based on labeling;
• Patent-term and terminal-disclaimer issues;
• FDA approval-stay timing;
• State-law and antitrust scrutiny of settlement terms;
• Commercial substitution and reimbursement barriers after approval.

Method-of-use claims can be particularly important where the label instructs use of naloxone nasal spray to reverse opioid overdose. A generic applicant may attempt a skinny label, omitting a patented indication or use. That approach is less effective where the approved generic label necessarily contains instructions that induce the patented use. [2]

Is biosimilar risk relevant to Narcan?

No. Biosimilar risk is not the relevant competitive framework for Narcan. Naloxone hydrochloride is a chemically synthesized small molecule, and generic applicants use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The relevant competitors are generic drug manufacturers and alternative naloxone products, including:

• Teva's naloxone nasal spray;
• Other approved or subsequently approved generic nasal sprays;
• Injectable naloxone products;
• Auto-injector products;
• Public-sector and institutional naloxone suppliers.

The absence of biosimilar litigation does not eliminate patent risk. Device and formulation patents can still delay or restrict generic entry.

How does Narcan compare with generic naloxone products?

Factor	Narcan	Teva generic naloxone nasal spray
Active ingredient	Naloxone hydrochloride	Naloxone hydrochloride
Route	Intranasal	Intranasal
Dose	4 mg per 0.1 mL device	4 mg per 0.1 mL device
Regulatory pathway	NDA	ANDA
Patent position	Protected by branded-product patent estate	Subject to Paragraph IV and settlement risk
Commercial position	Established brand, public recognition, broad distribution	Price-focused generic entrant
Biosimilar status	Not applicable	Not applicable
Principal risk to brand	Price erosion and formulary substitution	Patent enforcement and launch restrictions

The generic launch creates direct exposure to Narcan revenue, particularly in retail pharmacy, Medicaid, public-health programs, first-responder procurement, and institutional purchasing. The degree of erosion depends on substitution rules, payer coverage, supply reliability, contracting, and whether purchasers prioritize the Narcan brand.

What generic launch risks existed after settlement?

Teva's commercial risk did not end with settlement. The principal launch risks were:

1. Patent risk from later-issued or continuation patents;
2. Product-specific device differences creating manufacturing or quality issues;
3. FDA approval or supplement delays;
4. Supply-chain constraints for spray devices and naloxone API;
5. Reimbursement and pharmacy substitution barriers;
6. Additional litigation by patent owners or licensees;
7. Regulatory enforcement based on labeling or manufacturing compliance.

For Adapt and Emergent, the principal risk was sustained price erosion after the first generic launch. For Teva, the principal risks were delayed approval, litigation costs, launch restrictions, and the need to compete in a public-health market with substantial pricing pressure.

What geographic coverage did the Narcan patent estate have?

The U.S. litigation concerned U.S. patents and U.S. FDA approval. Adapt's broader commercial and patent strategy could include corresponding foreign applications and rights in Europe, Canada, Australia, and other markets, but foreign expiration dates, claim scope, opposition proceedings, and generic-entry rules differ by jurisdiction.

The Teva judgment therefore cannot be imported into foreign markets. A U.S. settlement does not automatically grant a worldwide license unless the agreement expressly provides one. Patent families must be reviewed jurisdiction by jurisdiction, including national-phase status, supplementary protection rights, patent-term adjustments, oppositions, and local regulatory exclusivity.

Key Takeaways

• Adapt Pharma sued Teva in D.N.J. civil action No. 2:18-cv-05752 over a proposed generic Narcan nasal spray.
• The dispute arose from Teva's Paragraph IV ANDA certification.
• The asserted technology involved intranasal naloxone formulation and nasal-delivery device claims.
• The case ended through settlement and dismissal, with no reported merits decision on validity, infringement, or enforceability.
• Teva later received FDA approval and launched a generic 4 mg naloxone hydrochloride nasal spray.
• Narcan faces generic price and market-share erosion rather than biosimilar competition.
• The public record does not establish the full settlement terms or support a definitive reverse-payment conclusion.
• Later-issued continuation patents and Orange Book updates remain relevant to ongoing generic-entry analysis.

FAQs

What was the docket number for Adapt Pharma v. Teva?

The case was filed as Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., No. 2:18-cv-05752, in the U.S. District Court for the District of New Jersey.

Did Teva win the Narcan patent lawsuit?

There was no reported merits victory for either side. The case was resolved by settlement and dismissal, so the docket does not establish that Teva defeated the patents or that Adapt proved infringement.

What generic drug did Teva launch after the lawsuit?

Teva launched naloxone hydrochloride nasal spray, 4 mg/0.1 mL, as a generic alternative to Narcan nasal spray.

Are Narcan patents still commercially relevant after Teva's approval?

Yes. FDA approval of one generic does not eliminate all patent rights. Orange Book-listed patents, continuation patents, device claims, and later-issued patents can affect additional applicants and future products.

Does Narcan have biosimilar competition?

No. Naloxone hydrochloride is a small-molecule drug. Competition proceeds through ANDA generics, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2015). Narcan (naloxone hydrochloride) nasal spray prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2021). FDA approves first generic naloxone hydrochloride nasal spray. FDA.

4. Teva Pharmaceuticals. (2021). Teva announces launch of first generic naloxone hydrochloride nasal spray in the United States. Teva Pharmaceuticals.

5. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).

6. U.S. District Court for the District of New Jersey. (2018). Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., No. 2:18-cv-05752, docket records.